Resources Contact Us Home
Browse by: INVENTOR PATENT HOLDER PATENT NUMBER DATE
 
 
Inventor:
McKernan; Patricia A.
Address:
Woodinville, WA
No. of patents:
13
Patents:












Patent Number Title Of Patent Date Issued
7101907 Topical administration of statins for treatment of bone disorders September 5, 2006
The topical administration of statins for the treatment of bone disorders is disclosed.
6642216 Isoprenoid pathway inhibitors for stimulating bone growth November 4, 2003
Compounds of the formula ##STR1##wherein X in each of formulas (1) and (2) represents a substituted or unsubstituted alkylene, alkenylene, or alkynylene linker of 2-6C; Y is of the formula ##STR2## or a stereoisomer thereof, wherein R.sup.1 is substituted or unsubstituted alkyl
6395740 Calcitonin mimetics May 28, 2002
Compounds are described which act as calcitonin mimetics. These compounds are useful in the treatment of diseases which are associated with bone resorption. Included among the calcitonin mimetics of the present invention are substituted piperazines. The calcitonin mimetics of the pre
6391917 Dialkyl ureas as calcitonin mimetics May 21, 2002
Dialkyl urea compounds are described which act as calcitonin mimetics. These compounds are useful in the treatment of diseases which are associated with bone resorption. The calcitonin mimetics of the present invention are also useful in assays for the determination of calcitonin rec
6376476 Isoprenoid pathway inhibitors for stimulating bone growth April 23, 2002
Various embodiments of statin compounds are shown to enhance the formation of bone and are thus useful in treating osteoporosis, bone fracture or deficiency, primary or secondary hyperparathyroidism, periodontal disease or defect, metastatic bone disease, osteolytic bone disease, post-pl
6255351 Dialkyl ureas as calcitonin mimetics July 3, 2001
Dialkyl urea compounds are described which act as calcitonin mimetics. These compounds are useful in the treatment of diseases which are associated with bone resorption. The calcitonin mimetics of the present invention are also useful in assays for the determination of calcitonin rec
6221913 Dialkyl ureas as calcitonin mimetics April 24, 2001
Dialkyl urea compounds are described which act as calcitonin mimetics. These compounds are useful in the treatment of diseases which are associated with bone resorption. The calcitonin mimetics of the present invention are also useful in assays for the determination of calcitonin rec
6124299 Calcitonin mimetics September 26, 2000
Compounds are described which act as calcitonin mimetics. These compounds are useful in the treatment of diseases which are associated with bone resorption. Included among the calcitonin mimetics of the present invention are substituted piperazines. The calcitonin mimetics of the pre
6080779 Compositions and methods for stimulating bone growth June 27, 2000
Compounds of the formula ##STR1## wherein X in each of formulas (1) and (2) represents a substituted or unsubstituted alkylene, alkenylene, or alkynylene linker of 2-6 C;Y represents one or more carbocyclic or heterocyclic rings; when two or more rings are present in Y, they may opti
6022887 Compositions and methods for stimulating bone growth February 8, 2000
Compounds of the formula ##STR1## wherein X in each of formulas (1) and (2) represents a substituted or unsubstituted alkylene, alkenylene, or alkynylene linker of 2-6C;Y represents one or more carbocyclic or heterocyclic rings; when two or more rings are present in Y, they may optio
5698521 Native calcitonin mimetics December 16, 1997
The invention provides isolated, biologically active native calcitonin mimetics and related methods. These small 16 and 17 amino acid proteins mimic the interaction of calcitonin on its receptor, and also exhibit bone resorptive inhibiting activity.
5677334 Method for inhibiting the stimulation of a glucagon-induced response pathway in a warm-blooded a October 14, 1997
Glucagon antagonists and methods relating thereto are disclosed. The glucagon antagonists include skyrin and skyrin analogs, and serve to inhibit the stimulation of a glucagon-induced response pathway, such as the adenylate cyclase response pathway or the inositol phosphate response
5508304 Glucagon antagonists and methods relating thereto April 16, 1996
Glucagon antagonists and methods relating thereto are disclosed. The glucagon antagonists include skyrin and skyrin analogs, and serve to inhibit the stimulation of a glucagon-induced response pathway, such as the adenylate cyclase response pathway or the inositol phosphate response










 
 
  Recently Added Patents
Printer driver, printer control method, and recording medium
Automated tuning in a virtual machine computing environment
Parallel processing computer systems with reduced power consumption and methods for providing the same
Method for producing SOI substrate and SOI substrate
Wheel
Error recovery storage along a memory string
Cylindrical LED fixture
  Randomly Featured Patents
Polypeptides having lactonohydrolase activity and nucleic acids encoding same
Narrow energy band gap gallium arsenide nitride semi-conductors and an ion-cut-synthesis method for producing the same
Object recognition device, object recognition method, program for object recognition method, and recording medium having recorded thereon program for object recognition method
Integrated investment management system with network datafeed and incremental database refresh
Power combiner/splitter
Inhibitors of P38
Prepayment wristband and computer debit system
Collection, storage and disposal system for refuse, trash or any other applicable materials
Heat sink and a method for manufacturing the same
Optical add-drop multiplexer